paliperidone-palmitate and Renal-Insufficiency

paliperidone-palmitate has been researched along with Renal-Insufficiency* in 1 studies

Other Studies

1 other study(ies) available for paliperidone-palmitate and Renal-Insufficiency

ArticleYear
The pharmacokinetics of risperidone in humans: a summary.
    The Journal of clinical psychiatry, 1994, Volume: 55 Suppl

    Risperidone is rapidly and completely absorbed after oral administration; less than 1% is excreted unchanged in the feces. The principal metabolite was found to be 9-hydroxyrisperidone. Hydroxylation of risperidone is subject to the same genetic polymorphism as debrisoquine and dextromethorphan. In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers. However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the "active fraction" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers. We found that risperidone exhibited linear elimination kinetics and that steady state was reached within 1 day for risperidone and within 5 days for the active fraction.

    Topics: Aged; Animals; Antipsychotic Agents; Biotransformation; Dogs; Half-Life; Humans; Isoxazoles; Liver Cirrhosis; Male; Paliperidone Palmitate; Piperidines; Pyrimidines; Rats; Reference Values; Renal Insufficiency; Risperidone; Schizophrenia

1994